Description

Reslizumab is a humanized monoclonal antibody (IgG4, kappa) specifically designed to target and neutralize interleukin-5 (IL-5), a key cytokine in eosinophilic inflammation. This targeted biological therapy is critical for the development of advanced treatments for severe eosinophilic asthma. It is primarily utilized by the global pharmaceutical industry for the formulation of innovative biologic drugs, meeting the stringent demands of modern precision medicine.

Application

• Pharmaceutical Active Ingredient (API): Primary use as the active component in biologic drug formulations for severe asthma.
• Clinical Research & Development: Serves as a critical reference standard and investigational material in pre-clinical and clinical studies targeting IL-5 pathways.
• Biopharmaceutical Manufacturing: Used in the large-scale production of therapeutic monoclonal antibodies under Good Manufacturing Practice (GMP) conditions.
• Drug Discovery & Validation: A key tool for validating IL-5 as a therapeutic target and for screening potential combination therapies.
• Reference Standard for QC: Acts as a high-purity standard for analytical method development and quality control testing in bioanalytical laboratories.

Basic Information

Product Name	Reslizumab
CAS No.	241473-69-8
Molecular Formula	C6452H9936N1696O2016S46
Molecular Weight	Approx. 146 kDa
Synonyms	SCH 55700; Reslizumab; Anti-IL-5 Monoclonal Antibody; Cinquil; Cinquilo; Reslizumab (USAN/INN); Anti-Interleukin-5 Monoclonal Antibody; IgG4-kappa, anti-(human interleukin 5) (human-mouse monoclonal SCH 55700 γ4-chain), disulfide with human-mouse monoclonal SCH 55700 κ-chain, dimer
EINECS	Contact for details

Quality Control

Our Reslizumab is produced and tested under stringent quality systems to ensure it meets the exacting standards required for pharmaceutical development and manufacturing. Each batch is accompanied by a comprehensive Certificate of Analysis (COA) detailing critical quality attributes such as purity, potency, aggregation, and biological activity. We adhere to relevant ICH guidelines and support compliance with cGMP for advanced therapeutic medicinal products (ATMPs).

Storage

Preserve in a tightly closed container, protected from light. Store at -20°C or below for long-term stability. This product is hygroscopic (moisture-sensitive) and strictly light-sensitive; it must be protected from all light exposure and moisture ingress. For short-term use, thawed aliquots may be stored at 2-8°C for a limited period as specified in the accompanying data sheet. Avoid repeated freeze-thaw cycles.

Specification

Item	Specification
Appearance	White to off-white lyophilized powder or clear to slightly opalescent solution
Identification (HPLC/MS)	Conforms to reference standard
Purity (SEC-HPLC)	≥ 98.0% (Monomer)
Protein Content (A280)	As per COA
Potency (Cell-based Assay)	≥ 90% relative to reference
Endotoxin (LAL)	< 1.0 EU/mg
Host Cell Proteins (HCP)	< 100 ppm
Residual DNA	< 10 pg/mg
Sterility (Membrane Filtration)	Sterile

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.